REG-Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
Oculis Holding AG completed randomization in PREDICT-1, its first genotype-based registration trial of Licaminlimab for TNFR1-mediated dry eye disease, enrolling 176 patients. Two-thirds of enrolled patients carry the TNFR1 genetic variant previously associated with stronger clinical response in Phase 2 studies, and topline results are expected around year-end 2026.
Key figures
- Drug Name
- Licaminlimab
- Phase Of Trial
- Pivotal (registration) Phase 3-style trial (PREDICT-1)
- Us ded patients
- ~40 million (diagnosed: ~20 million; moderate-to-severe: ~10 million)
- Genotype fraction
- 2/3 of enrolled patients carry the TNFR1 genetic variant
- Patients enrolled
- 176
- Topline data timing
- around year-end 2026
- Tnfr1 ded us patients
- 1.3-1.9 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.